Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $12.57 Consensus PT from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been given a consensus rating of “Buy” by the seven research firms that are presently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $12.57.

A number of research analysts have weighed in on the stock. Wedbush reissued an “outperform” rating and issued a $8.00 target price on shares of Sutro Biopharma in a research note on Wednesday, April 3rd. Piper Sandler reiterated an “overweight” rating and set a $11.00 price objective (down previously from $12.00) on shares of Sutro Biopharma in a research report on Wednesday, April 3rd. Oppenheimer restated an “outperform” rating and issued a $10.00 target price on shares of Sutro Biopharma in a report on Wednesday, April 3rd. HC Wainwright reduced their price target on Sutro Biopharma from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday, March 26th. Finally, JMP Securities reissued a “market outperform” rating and set a $17.00 price target on shares of Sutro Biopharma in a research report on Wednesday, April 3rd.

Insiders Place Their Bets

In other Sutro Biopharma news, insider Nicki Vasquez sold 12,185 shares of Sutro Biopharma stock in a transaction on Monday, January 29th. The stock was sold at an average price of $5.00, for a total value of $60,925.00. Following the sale, the insider now owns 12,803 shares in the company, valued at $64,015. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.90% of the stock is owned by insiders.

Institutional Trading of Sutro Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. lifted its position in Sutro Biopharma by 1,275.7% in the third quarter. Adage Capital Partners GP L.L.C. now owns 3,105,132 shares of the company’s stock valued at $10,775,000 after buying an additional 2,879,412 shares during the last quarter. Kynam Capital Management LP lifted its holdings in shares of Sutro Biopharma by 28.9% in the 4th quarter. Kynam Capital Management LP now owns 2,001,727 shares of the company’s stock worth $8,587,000 after acquiring an additional 449,052 shares during the last quarter. Parkman Healthcare Partners LLC boosted its position in shares of Sutro Biopharma by 1.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 1,202,431 shares of the company’s stock worth $5,158,000 after purchasing an additional 20,263 shares during the period. Acadian Asset Management LLC increased its holdings in Sutro Biopharma by 18.2% in the 3rd quarter. Acadian Asset Management LLC now owns 773,867 shares of the company’s stock valued at $2,684,000 after purchasing an additional 119,399 shares during the last quarter. Finally, Vontobel Holding Ltd. raised its position in Sutro Biopharma by 42.5% in the fourth quarter. Vontobel Holding Ltd. now owns 641,684 shares of the company’s stock valued at $2,753,000 after purchasing an additional 191,345 shares during the period. 96.99% of the stock is owned by institutional investors and hedge funds.

Sutro Biopharma Stock Performance

NASDAQ STRO opened at $3.72 on Wednesday. The business has a fifty day moving average price of $4.45 and a 200 day moving average price of $3.88. The company has a market cap of $232.28 million, a P/E ratio of -2.09 and a beta of 0.95. Sutro Biopharma has a one year low of $2.01 and a one year high of $6.13.

Sutro Biopharma (NASDAQ:STRO) last issued its earnings results on Monday, March 25th. The company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $1.24. The business had revenue of $113.72 million during the quarter, compared to analysts’ expectations of $12.16 million. Sutro Biopharma had a negative net margin of 69.47% and a negative return on equity of 71.42%. As a group, sell-side analysts predict that Sutro Biopharma will post -3.18 EPS for the current fiscal year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.